Page 24 - Priority Review News Today

- NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients -  - Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people...

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.

The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.

The FDA has accepted for priority review the application for tarlatamab to treat adults with advanced SCLC who have disease progression on or after platinum-based chemotherapy.

CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...

MAPS Public Benefit Corporation is seeking approval of its MDMA (midomafetamine capsules)-assisted therapy for posttraumatic stress disorder.

“ focused on areas that we believe will have the greatest impact for patients – both within and beyond medicine”

On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (“MAPS PBC”) announced it has submitted a new drug application (“NDA”) to the...

The FDA has accepted and granted priority review to the biologics license application seeking the approval of tarlatamab for the treatment of patients with advanced small cell lung cancer.

ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of...